CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding CRISPR Therapeutics AG changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 446 | 3 | 501 | +58 |
| Shares | 43.0M | 1.08M | 40.6M | −1.35M (−3.2%) |
| Value | $5.20B | $131.7M | $6.57B | +$1.50B (+29.7%) |
3 institutions that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (111)
Institutions that held CRISPR Therapeutics AG at the end of Q2 2021 but not at the end of Q1 2021.
Showing the largest 100 of 111 by value.
Sold out (53)
Institutions that held CRISPR Therapeutics AG at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (3)
Institutions that held CRISPR Therapeutics AG at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Waddell & Reed Financial Inc | 1,071,487 | $130.6M |
| Amundi Asset Management US, Inc. | 5,570 | $679.0K |
| Rikoon Group, LLC | 3,812 | $464.0K |